Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DG49 | ISIN: US4834971032 | Ticker-Symbol: 4XC1
Frankfurt
06.06.25 | 08:07
11,800 Euro
+1,72 % +0,200
1-Jahres-Chart
KALVISTA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
KALVISTA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,50012,80006.06.
12,10013,10006.06.

Aktuelle News zur KALVISTA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025199KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place...
► Artikel lesen
MoKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management201-Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials- -Sebetralstat data demonstrated rapid relief and resolution of severe...
► Artikel lesen
KALVISTA PHARMACEUTICALS Aktie jetzt für 0€ handeln
29.05.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference232KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45...
► Artikel lesen
22.05.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings265KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming congresses taking place concurrently from May 29-June 1, 2025: the 14th C1-inhibitor...
► Artikel lesen
12.05.KalVista Pharmaceuticals, Inc. - 8-K, Current Report1
02.05.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)305KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted three newly-hired employees inducement options to purchase an...
► Artikel lesen
30.04.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference210KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m....
► Artikel lesen
23.04.Kalvista stock holds $19 target, Market Outperform rating1
08.04.KalVista licenses commercialisation rights for HAE to Kaken in Japan3
08.04.KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal1
08.04.KalVista Pharma Licenses Sebetralstat For HAE To Kaken Pharma In Japan For Up To $22 Mln; Stocks Up-
08.04.KalVista Pharmaceuticals, Inc. - 8-K, Current Report1
08.04.KalVista rises after licensing deal with Kaken for lead asset in Japan1
08.04.KalVista schließt Lizenzvertrag für HAE-Medikament Sebetralstat in Japan ab1
08.04.KalVista inks Japan licensing deal for HAE drug sebetralstat3
08.04.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan237-Up to $24 million in upfront and milestone payments, plus royalties- -Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring commercial opportunity-...
► Artikel lesen
02.04.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)201KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted ten newly-hired employees inducement options to purchase an...
► Artikel lesen
31.03.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference205KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025...
► Artikel lesen
26.03.Stifel maintains Buy on Kalvista stock, price target steady at $391
26.03.Cantor Fitzgerald maintains Overweight on Kalvista shares1
Weiter >>
73 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1